View Ray Inc - Understand $vrayq stock

$VRAYQ Market Cap: $183.00

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$105.9M

TTM

Gross Margin

7.02%

TTM

Net Earnings

-$110.4M

TTM

Current Assets

$193.6M

Q1 2023

Current Liabilities

$166.8M

Q1 2023

Current Ratio

116.07%

Q1 2023

Total Assets

$233.2M

Q1 2023

Total Liabilities

$177.9M

Q1 2023

Book Value

$55.26M

Q1 2023

Cash

$81.30M

Q1 2023

P/E

-0.000001657

Nov 12, 2024 EST

Free Cash Flow

-$112.0M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$102.2M	$70.12M	$57.02M	$87.78M	$80.96M	$34.04M	$22.24M	$10.39M	$6.399M	$3.159M	$1.850M
YoY Change	45.76%	22.98%	-35.05%	8.42%	137.83%	53.09%	114.02%	62.37%	102.56%	70.76%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$102.2M	$70.12M	$57.02M	$87.78M	$80.96M	$34.04M	$22.24M	$10.39M	$6.399M	$3.159M	$1.850M
Cost Of Revenue	$92.16M	$69.78M	$61.08M	$93.26M	$74.36M	$25.49M	$1.969M	$14.54M	$9.151M	$8.187M	$3.710M
Gross Profit	$10.05M	$335.0K	-$4.059M	-$5.478M	$6.603M	$6.332M	-$3.629M	-$4.154M	-$2.752M	-$5.028M	-$1.860M
Gross Profit Margin	9.83%	0.48%	-7.12%	-6.24%	8.16%	18.6%	-16.32%	-39.98%	-43.01%	-159.16%	-100.54%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$82.93M	$72.14M	$76.91M	$91.52M	$65.18M	$39.79M	$29.10M	$26.82M	$19.42M	$13.29M	$9.520M
YoY Change	14.96%	-6.21%	-15.97%	40.43%	63.81%	36.71%	8.5%	38.1%	46.16%	39.59%
% of Gross Profit	825.54%	21532.84%			987.05%	628.35%
Research & Development	$32.43M	$31.85M	$25.01M	$23.79M	$16.52M	$14.71M	$11.44M	$10.45M	$9.404M	$8.780M	$8.160M
YoY Change	1.83%	27.36%	5.1%	44.03%	12.31%	28.55%	9.5%	11.11%	7.11%	7.6%
% of Gross Profit	322.86%	9507.16%			250.19%	232.3%
Depreciation & Amortization	$4.900M	$6.000M	$6.400M	$4.700M	$3.400M	$2.200M	$1.600M	$1.100M	$853.0K	$1.100M	$1.610M
YoY Change	-18.33%	-6.25%	36.17%	38.24%	54.55%	37.5%	45.45%	28.96%	-22.45%	-31.68%
% of Gross Profit	48.78%	1791.04%			51.49%	34.74%
Operating Expenses	$117.2M	$104.0M	$101.9M	$115.3M	$81.70M	$54.50M	$40.55M	$37.27M	$28.83M	$22.07M	$17.68M
YoY Change	12.68%	2.03%	-11.62%	41.16%	49.91%	34.41%	8.78%	29.3%	30.62%	24.82%
Operating Profit	-$107.1M	-$103.6M	-$106.0M	-$120.8M	-$75.09M	-$48.16M	-$44.18M	-$41.43M	-$31.58M	-$27.10M	-$19.54M
YoY Change	3.36%	-2.2%	-12.27%	60.86%	55.91%	9.03%	6.63%	31.19%	16.54%	38.67%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	$5.057M	$4.241M	$3.307M	$4.327M	$7.701M	$7.247M	$5.951M	$3.452M	$2.243M	-$90.00K	-$170.0K
YoY Change	19.24%	28.24%	-23.57%	-43.81%	6.26%	21.78%	72.39%	53.9%	-2592.22%	-47.06%
% of Operating Profit
Other Income/Expense, Net	$3.168M	-$2.171M	$585.0K	$3.202M	$6.389M	-$16.77M	-$512.0K	-$117.0K	$21.00K	-$30.00K	$0.00
YoY Change	-245.92%	-471.11%	-81.73%	-49.88%	-138.1%	3175.39%	337.61%	-657.14%	-170.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$107.3M	-$110.0M	-$107.9M	-$120.2M	-$76.40M	-$72.18M	-$50.64M	-$44.99M	-$33.80M	-$27.22M	-$19.71M
YoY Change	-2.47%	1.98%	-10.23%	57.34%	5.85%	42.54%	12.54%	33.12%	24.17%	38.1%
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$1.000K	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$107.3M	-$110.0M	-$107.9M	-$120.2M	-$76.40M	-$72.18M	-$50.64M	-$45.00M	-$33.80M	-$27.22M	-$19.71M
YoY Change	-2.45%	1.94%	-10.23%	57.34%	5.85%	42.54%	12.54%	33.12%	24.17%	38.1%
Net Earnings / Revenue	-104.98%	-156.88%	-189.26%	-136.93%	-94.36%	-212.02%	-227.71%	-433.06%	-528.21%	-861.67%	-1065.41%
Basic Earnings Per Share	-$0.59	-$0.67	-$0.73	-$1.18
Diluted Earnings Per Share	-$0.59	-$0.67	-$0.73	-$1.18	-$941.8K	-$1.235M	-$1.264M	-$1.180M	-$886.4K	-$713.9K	-$516.9K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$136.0M	$218.3M	$156.7M	$226.8M	$167.4M	$57.40M	$14.20M	$20.70M	$11.10M	$26.50M	$4.100M
YoY Change	-37.73%	39.34%	-30.91%	35.48%	191.64%	304.23%	-31.4%	86.49%	-58.11%	546.34%
Cash & Equivalents	$136.0M	$218.3M	$156.7M	$226.8M	$167.4M	$57.40M	$14.20M	$20.70M	$11.10M	$26.50M	$4.100M
Short-Term Investments
Other Short-Term Assets	$12.22M	$9.145M	$7.300M	$6.800M	$15.70M	$18.60M	$6.900M	$10.10M	$5.300M	$300.0K	$100.0K
YoY Change	33.67%	25.27%	7.35%	-56.69%	-15.59%	169.57%	-31.68%	90.57%	1666.67%	200.0%
Inventory	$38.79M	$34.40M	$48.70M	$61.50M	$57.60M	$26.40M	$10.60M	$12.00M	$11.00M	$7.900M	$6.400M
Prepaid Expenses
Receivables	$41.38M	$21.66M	$11.80M	$16.80M	$36.90M	$20.30M	$4.200M	$800.0K	$900.0K	$300.0K	$0.00
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$228.4M	$283.5M	$224.4M	$311.9M	$277.7M	$122.7M	$35.90M	$43.60M	$28.40M	$34.90M	$10.60M
YoY Change	-19.47%	26.36%	-28.05%	12.32%	126.32%	241.78%	-17.66%	53.52%	-18.62%	229.25%
Property, Plant & Equipment	$25.59M	$29.90M	$34.20M	$35.10M	$14.00M	$11.60M	$11.60M	$7.300M	$2.900M	$1.800M	$1.800M
YoY Change	-14.44%	-12.56%	-2.56%	150.71%	20.69%	0.0%	58.9%	151.72%	61.11%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.419M	$8.313M	$2.900M	$3.000M	$3.300M	$1.400M	$1.200M	$1.000M	$2.500M	$500.0K	$600.0K
YoY Change	1.28%	186.66%	-3.33%	-9.09%	135.71%	16.67%	20.0%	-60.0%	400.0%	-16.67%
Total Long-Term Assets	$43.04M	$38.26M	$37.20M	$38.10M	$17.30M	$13.00M	$12.90M	$8.600M	$5.700M	$2.800M	$2.400M
YoY Change	12.5%	2.85%	-2.36%	120.23%	33.08%	0.78%	50.0%	50.88%	103.57%	16.67%
Total Assets	$271.4M	$321.8M	$261.6M	$350.0M	$295.0M	$135.7M	$48.80M	$52.20M	$34.10M	$37.70M	$13.00M
YoY Change
Accounts Payable	$28.30M	$9.199M	$10.00M	$13.70M	$10.20M	$11.00M	$5.000M	$4.400M	$6.100M	$2.300M	$3.000M
YoY Change	207.64%	-8.01%	-27.01%	34.31%	-7.27%	120.0%	13.64%	-27.87%	165.22%	-23.33%
Accrued Expenses	$27.54M	$28.02M	$20.00M	$22.60M	$9.200M	$7.100M	$6.300M	$5.200M	$3.900M	$4.000M	$2.200M
YoY Change	-1.71%	40.11%	-11.5%	145.65%	29.58%	12.7%	21.15%	33.33%	-2.5%	81.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$200.0K	$200.0K	$200.0K
YoY Change								-100.0%	0.0%	0.0%
Long-Term Debt Due	$0.00	$3.222M	$0.00	$1.600M				$0.00	$5.500M	$0.00	$0.00
YoY Change	-100.0%		-100.0%					-100.0%
Total Short-Term Liabilities	$96.58M	$76.24M	$56.90M	$59.10M	$53.90M	$56.20M	$37.20M	$28.20M	$29.80M	$9.900M	$8.000M
YoY Change	26.68%	33.99%	-3.72%	9.65%	-4.09%	51.08%	31.91%	-5.37%	201.01%	23.75%
Long-Term Debt	$73.34M	$54.03M	$56.90M	$54.00M	$55.40M	$44.50M	$44.30M	$29.00M	$9.300M	$14.50M	$0.00
YoY Change	35.74%	-5.04%	5.37%	-2.53%	24.49%	0.45%	52.76%	211.83%	-35.86%
Other Long-Term Liabilities	$19.23M	$21.74M	$17.40M	$20.80M	$18.40M	$33.00M	$10.90M	$1.900M	$600.0K	$300.0K	$14.80M
YoY Change	-11.53%	24.94%	-16.35%	13.04%	-44.24%	202.75%	473.68%	216.67%	100.0%	-97.97%
Total Long-Term Liabilities	$92.57M	$75.77M	$74.30M	$74.80M	$73.80M	$77.50M	$55.20M	$30.90M	$9.900M	$14.80M	$14.80M
YoY Change	22.17%	1.98%	-0.67%	1.36%	-4.77%	40.4%	78.64%	212.12%	-33.11%	0.0%
Total Liabilities	$189.2M	$152.0M	$131.3M	$133.8M	$127.7M	$133.7M	$92.40M	$59.10M	$39.60M	$24.80M	$22.70M
YoY Change	24.43%	15.77%	-1.87%	4.78%	-4.49%	44.7%	56.35%	49.24%	59.68%	9.25%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2022	2021	2020	2019
Basic Shares Outstanding	180.7M shares	164.5M shares	147.9M shares	102.0M shares
Diluted Shares Outstanding	180.7M shares	164.5M shares	147.9M shares	102.0M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $183.00

About ViewRay Inc

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. The company is headquartered in Oakwood Village, Ohio and currently employs 295 full-time employees. The company went IPO on 2014-11-04. The MRIdian MR-Guided Radiation Therapy System integrates diagnostic MR imaging with radiation therapy delivery to enable on-table adaptive treatments with real-time tissue tracking and automatic beam gating. The MRIdian is comprised of three components, namely magnetic resonance imaging (MRI) system, radiation delivery system, and integrated treatment planning and delivery software. MRIdian employs MRI-based technology to provide real-time imaging that targets tumors from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. MRIdian offers MR-guided imaging that provides tissue visualization compared to cone-beam computed tomography (CBCT), to enable contouring and reduced margins. The firm has installed approximately 56 MRIdian systems at hospitals, which are used to treat a variety of solid tumors.

Industry: Electromedical & Electrotherapeutic Apparatus Peers: Abbott Laboratories Cutera Inc AngioDynamics Inc Artivion Inc Senseonics Holdings Inc Cardiovascular Systems Inc HESKA CORP Outset Medical Inc Mesa Laboratories Inc SI-BONE Inc